Principal investigators
The Lipoprotein(a) Studies Collaboration is jointly led by Peter Willeit (Medical University of Innsbruck) and Sotirios Tsimikas (University of Califonia-San Diego).
Key publication
The key publication from this collaboration has been published in the Lancet on 4 October 2018. Please click on the subsequent links to obtain full-text and a slide deck.
![](https://clinicalepi.i-med.ac.at/wp-content/uploads/2018/10/Willeit_Lancet_2018_accepted_version2.png)
![](https://clinicalepi.i-med.ac.at/wp-content/uploads/2018/10/Lp_a_Studies_Collaboration_Slide_deck.png)
Rationale
- Lipoprotein(a) [Lp(a)] is a lipoprotein composed of apolipoprotein(a) covalently bound to apolipoprotein B of a low-density lipoprotein-like particle.
- Lp(a) is an established risk factor for cardiovascular disease. Lp(a) has pro-inflammatory and pro-thrombotic properties and may thereby promote the developement of atherosclerosis.
- In contrast to other major lipoproteins, there is currently no approved specific therapy available to lower circulating plasma levels of Lp(a).
![](https://clinicalepi.i-med.ac.at/wp-content/uploads/2018/07/Protein_LPA_PDB_1i71-e1530703866586.png)
Overarching aim
Lipoprotein(a) Studies Collaboration (LPASC) has harmonised Lp(a) data from prospective cohort studies and clinical trials. The overarching aim of the consortium is to:
- better understand the role of Lp(a) as a independent risk marker in the primary vs. secondary prevention setting,
- characterise the effects of different medications on Lp(a) concentration, and
- evaluate the usefulness of Lp(a) measurements in risk prediction models over and beyond information on conventional risk factors.
Collaborating studies
Cohort | Study design | Years of baseline | Population type | Country |
---|---|---|---|---|
4D | Clinical trial (Atorvastatin) | 1998-2002 | Type 2 diabetes + hemodialysis | Germany |
4S | Clinical trial (Simvastatin) | 1989-1990 | Prior myocardial infarction or angina | Scandinavian countries |
AFCAPS | Clinical trial (Lovastatin) | 1990-1993 | General population | USA |
ASTRONOMER | Clinical trial (Rosuvastatin) | 2002-2005 | Asymptomatic mild to moderate aortic stenosis | Canada |
CARDS | Clinical trial (Atorvastatin) | 1997-2001 | Type 2 diabetes | UK & Ireland |
FHCHILDREN | Clinical trial (Pravastatin) | 1997-1999 | Homozygous familial hypercholesterolemia | The Netherlands |
JUPITER | Clinical trial (Rosuvastatin) | 2003-2006 | General population with C-reactive protein >2mg/dL | Multinational |
LIPID | Clinical trial (Pravastatin) | 1990-1992 | Prior myocardial infarction or unstable angina | Australia & NZ |
MIRACL | Clinical trial (Atorvastatin) | 1997-1999 | Acute coronary syndrome | Multinational |
PRINCE | Clinical trial (Pravastatin) | 2000 | Primary and secondary prevention | USA |
PROVE-IT | Clinical trial (Pravastatin & Atorvastatin) | 2000-2001 | Acute myocardial infarction or high-risk unstable angina | Multinational |
PROXI | Clinical trial (Pravastatin & Atorvastatin) | 2001-2002 | General population | USA |
REVERSAL | Clinical trial (Pravastatin & Atorvastatin) | 1999-2001 | Coronary stenosis | USA |
TNT | Clinical trial (Atorvastatin) | 1989-1990 | Coronary heart disease | Multinational |
VISION | Clinical trial (Pitavastatin & Atorvastatin) | 2006 | Hypercholesterolemia | Japan |
Additional publications
![](https://clinicalepi.i-med.ac.at/wp-content/uploads/2021/01/LPA1.png)